Stock AnalizMaze Therapeutics, Inc. MAZE
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2025 · data as of November 13, 2026
Maze Therapeutics, Inc. (MAZE) is a healthcare company listed in the US with a market value of about $1.9B. In the twelve months to September 30, 2026 it had revenue of $20M and net income of -$151M, a net margin of -757.4%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -38%.
Score: 0.6 / 5
Checks passed
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 2 years
| Fiscal year | TTM | 2025 | 2024 |
|---|---|---|---|
| Revenue | $20M | — | $168M |
| Net income | -$151M | -$131M | $52M |
| Free cash flow | -$115M | -$113M | $75M |
| EPS (diluted) | $-2.60 | $-3.05 | $1.25 |
| Net margin | -757.4% | — | 31.2% |
| ROIC | — | -37.8% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 13 analysts is $62.46, 82% above the current price; targets range from $46.00 to $110.00; the consensus rating is “Strong buy”; expected EPS is $-2.85 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Maze Therapeutics pay a dividend?
Not currently.
Is Maze Therapeutics a good stock to buy?
We do not give buy or sell advice. Maze Therapeutics scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.